The most common pharmacological therapeutic strategies for patients with ER+ breast cancer are endocrine therapies including selective estrogen receptors α (ERα) modulators, such as tamoxifen, selective ERα down-regulators and aromatase inhibitors (AIs)2. The gene discussed is CYP19A1; the disease is breast cancer.